Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients
| Autor: | Gerald Aichinger, Nicole Hetzelt, Otfried Kistner, Richard Fritz, P. Noel Barrett, Reinhard Ilk, M. Keith Howard, Thomas R. Kreil, Maikel V. W. van der Velden, Daniel Portsmouth, Christine Hohenadl |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
risk populations
biology H5N1 vaccine business.industry Influenza vaccine Antibody titer virus diseases neuraminidase medicine.disease_cause Virology Influenza A virus subtype H5N1 Vaccination Infectious Diseases Oncology vero cell culture Immunology biology.protein Vero cell Medicine Brief Reports avian influenza Antibody influenza vaccine business Neuraminidase |
| Zdroj: | Open Forum Infectious Diseases |
| ISSN: | 2328-8957 |
| Popis: | Neuraminidase-inhibiting (NAi) antibodies have been reported to be an independent correlate of protection from influenza disease, but the NAi antibody response to influenza vaccination has never been assessed in chronically ill or immunocompromised participants. Using an enzyme-linked lectin assay, we demonstrated that 2 immunizations with a Vero cell culture-derived, whole-virus H5N1 A/Vietnam vaccine induces NAi antibodies in 94.3% of chronically ill and 83.8% of immunocompromised participants. A booster with a heterologous A/Indonesia H5N1 vaccine induced comparable NAi antibody titers in both groups and resulted in 100% seropositivity. These data support prepandemic H5N1 vaccination strategies for these highly vulnerable risk groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|